|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||29.48 - 29.48|
|52-week range||29.48 - 52.94|
|Beta (5Y monthly)||1.21|
|PE ratio (TTM)||8.70|
|Forward dividend & yield||0.96 (3.27%)|
|Ex-dividend date||16 May 2022|
|1y target est||13.74|
In Germany, 250 jobs would be affected, the paper said. Fresenius, which runs dialysis centers and hospitals, makes generic drugs and helps plan hospital construction projects, last year launched a group-wide cost cutting programme to become more competitive amid a declining share price over several years.
German healthcare group Fresenius's first-quarter profit exceeded market expectations on Wednesday, driven by growth in its generic infusion drugs unit in emerging markets. However, the group warned cost inflation and supply chain disruptions were likely to increase this year, fuelled by Russia's invasion of Ukraine. Fresenius's businesses include the Helios hospital chain, drugmaker Kabi, medical services firm Vamed and dialysis specialist Fresenius Medical Care (FMC).
Omnicell (OMCL), Fresenius Kabi collaborate to offer safe and efficient dispensing of controlled substances across hospitals and health systems in the United States.